drugset / Trial / NCT04002089

Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety, of EXPAREL Administered as Sciatic Nerve Block (In Popliteal Fossa), for Postsurgical Analgesia in Subjects Undergoing Bunionectomy

NCT04002089

Phase 1 Completed 45 enrolled Pacira Pharmaceuticals, Inc
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a pilot, open label, single center study in 40 subjects undergoing bunionectomy. The study will assess and collect information on pharmacokinetics, pharmacodynamics, safety and efficacy of EXPAREL administered as a sciatic nerve block (in popliteal fossa). A total of 10 subjects will be enrolled in each of the 4 cohorts.

Timeline

Start
2019-07-26
Primary completion
2019-12-02
Completion
2019-12-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 100 mg Other
Subject Bupivacaine Other / unclassified 133 mg Other
Subject Bupivacaine Other / unclassified 266 mg Other

Indications